Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
BUSINESS
Takeda’s Japan Ethical Sales Sag 6.8% on LLP Transfer, but Underlining Revenue Grows
Takeda Pharmaceutical said on May 10 that it saw its Japan ethical drug sales fall 6.8% year on year to 504.7 billion yen in the year ended March 2017 due to the divestiture of long-listed products (LLPs), or off-patent brand-name…
To read the full story
Related Article
- Takeda Delivers Double-Digit Profit Growth as Entyvio Nets 200-Plus Billion Yen
May 15, 2018
- Takeda Logs 3.6% Sales Rise, Double-Digit Profit Jump on Entyvio, Takecab
November 2, 2017
- There Could Be Discussions on Price Reviews for Add’l Indication-Driven Sales Growth: Weber
May 11, 2017
- Takeda’s Half-Year Sales Slip on LLP Transfer, but Profits Zoom
October 31, 2016
- Takeda Enjoys Higher Revenues and Profits as Entyvio Sales Triple
May 11, 2016
BUSINESS
- Mochida Lifts G-Lasta Biosimilar Shipment Curbs after Over 2 Years
November 4, 2026
- Espha Taps Korean Eylea Follow-On for First Biosimilar Foray
November 4, 2026
- Kyowa Kirin Won’t Stop Drug Launches over MFN Pricing: CEO
November 4, 2026
- Takara Bio, S-RACMO Finalize Cell Processing CDMO Transfer for January
November 4, 2026
- Roche Launches CDx for Takeda’s Elahere in Japan
November 4, 2026
Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…